Prior to 2011, the treatment for PDAC was mainly gemcitabine in both the adjuvant and palliative setting. However, two landmark studies established FOLFIRINOX and protein-bound paclitaxel and gemcitabine as frontline regimens for the treatment of metastatic PDAC.2,3 Read more . . .
Pancreatic ductal adenocarcinoma (PDAC) carries a high mortality rate and is the fourth leading cause of cancer-related mortality in the United States.